

Endometrial Cancer - Pipeline Review, H2 2020

<https://marketpublishers.com/r/EDB45DD5E76EN.html>

Date: November 2020

Pages: 1759

Price: US\$ 2,500.00 (Single User License)

ID: EDB45DD5E76EN

Abstracts

Endometrial Cancer - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Pipeline Review, H2 2020, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved

in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 84, 66, 3, 20, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 2 and 2 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Endometrial Cancer - Overview

Endometrial Cancer - Therapeutics Development

Endometrial Cancer - Therapeutics Assessment

Endometrial Cancer - Companies Involved in Therapeutics Development

Endometrial Cancer - Drug Profiles

Endometrial Cancer - Dormant Projects

Endometrial Cancer - Discontinued Products

Endometrial Cancer - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Endometrial Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Endometrial Cancer - Pipeline by Aadi Bioscience Inc, H2 2020
Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2020
Endometrial Cancer - Pipeline by Abpro Corp, H2 2020
Endometrial Cancer - Pipeline by Acepodia Biotech Inc, H2 2020
Endometrial Cancer - Pipeline by Acrotech Biopharma LLC, H2 2020
Endometrial Cancer - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2020
Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020
Endometrial Cancer - Pipeline by Agenus Inc, H2 2020
Endometrial Cancer - Pipeline by Allarity Therapeutics A/S, H2 2020
Endometrial Cancer - Pipeline by Almac Discovery Ltd, H2 2020
Endometrial Cancer - Pipeline by Alphamab Oncology, H2 2020
Endometrial Cancer - Pipeline by Amgen Inc, H2 2020
Endometrial Cancer - Pipeline by Amphivena Therapeutics Inc, H2 2020
Endometrial Cancer - Pipeline by Apexian Pharmaceuticals Inc, H2 2020
Endometrial Cancer - Pipeline by Apexigen Inc, H2 2020
Endometrial Cancer - Pipeline by Apollomics Inc, H2 2020
Endometrial Cancer - Pipeline by Arch Oncology Inc, H2 2020
Endometrial Cancer - Pipeline by Arcus Biosciences Inc, H2 2020
Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2020
Endometrial Cancer - Pipeline by Ascenta Therapeutics Inc, H2 2020
Endometrial Cancer - Pipeline by AstraZeneca Plc, H2 2020
Endometrial Cancer - Pipeline by Bantam Pharmaceutical LLC, H2 2020
Endometrial Cancer - Pipeline by Bavarian Nordic A/S, H2 2020
Endometrial Cancer - Pipeline by Bayer AG, H2 2020
Endometrial Cancer - Pipeline by BeiGene Ltd, H2 2020
Endometrial Cancer - Pipeline by Beijing Neoantigen Biotechnology Co Ltd, H2 2020

Endometrial Cancer - Pipeline by Bicycle Therapeutics Plc, H2 2020
Endometrial Cancer - Pipeline by Bio-Path Holdings Inc, H2 2020
Endometrial Cancer - Pipeline by BioAtla LLC, H2 2020
Endometrial Cancer - Pipeline by BioMed Valley Discoveries Inc, H2 2020
Endometrial Cancer - Pipeline by BioNTech SE, H2 2020
Endometrial Cancer - Pipeline by Black Diamond Therapeutics Inc, H2 2020
Endometrial Cancer - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Endometrial Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2020
Endometrial Cancer - Pipeline by Byondis BV, H2 2020
Endometrial Cancer - Pipeline by Carrick Therapeutics Ltd, H2 2020
Endometrial Cancer - Pipeline by Celon Pharma SA, H2 2020
Endometrial Cancer - Pipeline by Celsion Corp, H2 2020
Endometrial Cancer - Pipeline by Checkpoint Therapeutics Inc, H2 2020
Endometrial Cancer - Pipeline by Clovis Oncology Inc, H2 2020
Endometrial Cancer - Pipeline by Compugen Ltd, H2 2020
Endometrial Cancer - Pipeline by Context Therapeutics LLC, H2 2020
Endometrial Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2020
Endometrial Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H2 2020
Endometrial Cancer - Pipeline by CStone Pharmaceuticals Co Ltd, H2 2020
Endometrial Cancer - Pipeline by Cue Biopharma Inc, H2 2020
Endometrial Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2020
Endometrial Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Endometrial Cancer - Pipeline by Deciphera Pharmaceuticals Inc, H2 2020
Endometrial Cancer - Pipeline by Dragonfly Therapeutics Inc, H2 2020
Endometrial Cancer - Pipeline by Eisai Co Ltd, H2 2020
Endometrial Cancer - Pipeline by Eli Lilly and Co, H2 2020
Endometrial Cancer - Pipeline by Elicio Therapeutics, H2 2020
Endometrial Cancer - Pipeline by ENB Therapeutics LLC, H2 2020
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2020
Endometrial Cancer - Pipeline by Esperas Pharma Inc, H2 2020
Endometrial Cancer - Pipeline by EstryX Pharma Ltd, H2 2020
Endometrial Cancer - Dormant Projects, H2 2020
Endometrial Cancer - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Endometrial Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

I would like to order

Product name: Endometrial Cancer - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/EDB45DD5E76EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EDB45DD5E76EN.html>